PERSANTIN--A DOUBLE BLIND STUDY
- Lipoprotein(a) plays only a supporting role in heart disease. // Modern Medicine;Jun98, Vol. 66 Issue 6, p35
Presents an abstract of the article `Is Lipoprotein(a) an Independent Risk Factor for Ischemic Heart Disease in Men?,' by B. Cantin, F. Gagnon, et al from the `Journal of American College Cardiology,' dated March 1, 1998.
- The effect of ranolazine on the vasodilator-induced myocardial perfusion abnormality. Venkataraman, Rajesh; Aljaroudi, Wael; Belardinelli, Luiz; Heo, Jaekyeong; Iskandrian, Ami // Journal of Nuclear Cardiology;Jun2011, Vol. 18 Issue 3, p456
Background: We previously reported that ranolazine improved myocardial ischemia during exercise myocardial perfusion imaging (MPI). Since the mechanism of reversible perfusion defects is different in exercise than vasodilator MPI, and based on the mechanism of action of ranolazine, we...
- Aspirin and Clopidogrel: Efficacy, Treatment, and Resistance in Coronary Artery Disease. Maksoud, Aziz; Candipan, Robert C.; Wilson, David B.; Vacek, James L. // International Journal of Angiology (Springer Science & Business ;Fall2005, Vol. 14 Issue 3, p109
Oral antiplatelet therapy is a key element of the continuously evolving treatment of acute coronary syndromes. As part of this evolution, resistance to oral antiplatelet therapy has emerged as a new challenge adversely affecting patientsâ€™ clinical risk and outcome. This review addresses...
- Exogenous hydrogen sulfide (H2S) protects against regional myocardial ischemiaâ€“reperfusion injury. Johansen, David; Ytrehus, Kirsti; Baxter, Gary // Basic Research in Cardiology;Jan2006, Vol. 101 Issue 1, p53
Hydrogen sulfide (H2S) is a gaseous mediator, produced by the metabolic pathways that regulate tissue concentrations of sulfurâ€“containing amino acids. Recent studies indicate that endogenous or exogenous H2S exerts physiological effects in the cardiovascular system of vertebrates,...
- Blood Type Linked to Heart Disease Risk, But Clinical Significance Unlikely. Mitka, Mike // JAMA: Journal of the American Medical Association;10/3/2012, Vol. 308 Issue 13, p1306
The article presents information on link between blood group type and heart disease risks. It informs that new research suggests that blood type is associated with varying levels of risk of developing coronary heart disease but the experts says that the research is not clinically significant. It...
- Framework for Evaluating Novel Risk Markers. Hlatky, Mark A. // Annals of Internal Medicine;3/20/2012, Vol. 156 Issue 6, p468
An introduction to the journal is presented which discusses the importance of identifying novel risk markers for Coronary Heart Disease (CHD) and their role in drug development.
- P38 MAPK ACTIVATION IN MYOCARDIAL ISCHAEMIA. KUMPHUNE, S. // International Journal of Pharma & Bio Sciences;Apr-Jun2011, Vol. 2 Issue 2, pB.107
Ischaemic heart disease remains, and is likely to continue to be, the leading life threatening disease around the world. Signaling pathways have become more interesting as novel therapeutic targets in ischaemic heart disease. However, one needs to be very careful in picking the therapeutic...
- Telemedicine cost effective in acute ischaemic stroke. // PharmacoEconomics & Outcomes News;2/18/2012, Issue 647, p6
The article focuses on a study which investigated the cost effectiveness of telemedicine in acute ischaemic stroke patients.
- Unlocking protein diversity. // Pharmaceutical Technology Europe;Nov2005, Vol. 17 Issue 11, p10
Reports on the discovery of the mechanism by which a simple organism can produce 10 trillion varieties of a single protein. Significance of the discovery to provide a new tool to develop novel drugs; Move of researchers to recreate the process in a test tube to allow them to target new proteins...